IDH1 and glioma: Patients with IDH1/2 mut gliomas and high Ki-67 expression survived longer than did those with IDH1/2 wt gliomas and moderate Ki-67 expression (Median OS = 566 vs. 434 days), which contradicts the findings in Figure 1B.